In a groundbreaking move for the Indian biotech industry, IXP, a venture capital firm focused on life sciences, has launched its very first fund, the IXP Lifesciences Catalyst Fund. With an ambitious ₹200 crore target, this fund will be investing in early-stage biotech startups that are working on cutting-edge innovations in healthcare, biotechnology, pharmaceuticals, and more. But that’s not…
